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Purpose
Nasopharyngeal carcinoma (NPC), displays a marked geographic variation is endemic in east and southeast parts of Asia.
Though induction chemotherapy (IC) offers thereotical advantages for locally advanced (LA) NPC, such as potentially eradicating micrometastases and debulking of tumour, the effects of IC in such patients on overall survival (OS) and progression free survival (PFS) remain controversial.
Hence, we performed a systematic review and meta-analysis of both RCTs and OBS to determine and compare the effects of addition of IC to CCRT vs CCRT alone on OS and PFS and adverse events (AE) for patients with LA-NPC.
Methods and materials
This meta-analysis incorporated both RCTs and OBS that included treatment-naïve patients with histologically proven non-metastatic, Stage III to IV NPC with the following trial design: IC followed by CCRT vs CCRT. Only trials with unconfounded comparisons of IC were included. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.
We searched MEDLINE via PubMed for eligible studies comparing IC plus CCRT versus CCRT for LA-NPC from Jan 1996 to May 2017. The search strategy included the medical subject headings of "nasopharyngeal neoplasm", "drug therapy", and "radiotherapy".
The search included trial reports published in the English and Chinese languages. The search was supplemented by manual search of reference lists of included studies, review articles, chapter reference lists of textbooks, and meeting proceedings of ASCO, American Society for Radiation Oncology and international conference on innovative approaches in head and neck oncology. Prospective and ongoing trials were identified by searching the prospective trial registers: http://www.clinicaltrials.gov and http:// www.who.int/trialsearch.
